Search results
Results From The WOW.Com Content Network
Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012: [1]. Pegylated interferon-alpha-2a; Pegylated interferon-alpha-2b ...
A 2013 meta-analysis over Clinical Infectious Diseases noted the combination-treatment to be safe as well as effective for children and adolescents; other meta-analyses had noted the same for adult population. [9] A 2012 meta-analysis had found PEGylated interferon alfa-2a to be the more effective variant for treatment-naive patients. [10]
Peginterferon alfa-2a is a long acting interferon. Interferons are proteins released in the body in response to viral infections . Interferons are important for fighting viruses in the body, for regulating reproduction of cells , and for regulating the immune system.
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. [ 4 ] [ 5 ] The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the ...
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
In the United States, as of 2015, the cost is between US$1,284 and US$1,386 per 30 mcg vial. [31] As of 2020, the National Average Drug Acquisition Cost (NADAC) in the United States for Avonex was $6,872.94 for a 30 mcg kit. [32] Avonex and Rebif are on the top ten best-selling multiple sclerosis drugs of 2013. [33]
Peginterferon alfa-2a (Pegasys) – PEGylated interferon alpha for use in the treatment of chronic hepatitis C and hepatitis B (Hoffmann-La Roche, 2002) Peginterferon alfa-2b (PegIntron) – PEGylated interferon alpha for use in the treatment of chronic hepatitis C and hepatitis B (Schering-Plough/Enzon, 2000)
On one hand, this agent offers up to a 95% response rate as part of an interferon-free treatment regimen for hepatitis C. Generally speaking, it is more effective and better tolerated than alternative treatments. Unfortunately, the current per pill cost—$1,000—results in an $84,000 treatment course, creating barriers to therapy for many.